KDM5亚家族在胃癌中的作用及免疫浸润的初步分析
Preliminary Analysis of the Role of the KDM5 Subfamily in Stomach Adenocarcinoma and Immune Infiltration
DOI: 10.12677/ACM.2023.13102236, PDF,   
作者: 赵立军：长治医学院研究生院，山西 长治；渠 海*：长治医学院附属和济医院普外肝胆科，山西 长治
关键词: KDM5亚家族；胃癌；免疫微环境；KDM5 Subfamily； Stomach Adenocarcinoma (Gastric Cancer)； Immune Microenvironment
摘要: 胃癌为全球范围内的重大恶性疾病，免疫治疗的出现极大改善了部分患者的预后，但仍有相当一部分患者表现出较差的治疗效果，故迫切需要新的生物标志物出现，本文旨在探究KDM5亚家族用于预测胃癌预后及免疫治疗的可能。我们的结果显示，KDM5B表达与患者预后呈负相关，ROC曲线(1年、3年和5年AUC分别为0.538、0.527、0.575)表明其对患者预后具有较强预测能力。KEGG和GO功能富集分析等显示其可能参与肿瘤的增殖、免疫逃逸、PI3K-AKT-mTOR、细胞铁死亡等生物过程，随后对免疫微环境的探究，发现KDM5B异常表达与免疫检查点LAG3 (P < 0.01)、PDCD1 (P < 0.01)表达差异具有明显相关性。总之，KDM5B可能作为胃癌的相关生物标志物，并可能作为一种新的免疫靶向手段作用于胃癌。
Abstract: Stomach Adenocarcinoma (or Gastric cancer) represents a significant global malignancy, and while the advent of immunotherapy has led to improved prognoses in some patients, a substantial pro-portion still experiences unfavorable treatment outcomes. Thus, there is an urgent demand for the identification of novel biomarkers. This study aims to investigate the potential utility of the KDM5 subfamily in predicting the prognosis of gastric cancer and its responsiveness to immunotherapy. Our findings revealed a negative correlation between KDM5B expression and patient prognosis. ROC curves demonstrated its robust predictive capacity for patient outcomes, with 1-, 3-, and 5-year AUCs of 0.538, 0.527, and 0.575, respectively. Functional enrichment analyses, including KEGG and GO, suggested its involvement in pivotal biological processes such as tumor proliferation, immune evasion, PI3K-AKT-mTOR signaling, cellular iron death, and others. Further exploration of the im-mune microenvironment unveiled a significant association between aberrant KDM5B expression and altered expression levels of immune checkpoints LAG3 (P < 0.01) and PDCD1 (P < 0.01). In summary, KDM5B holds promise as a pertinent biomarker for gastric cancer and a potential novel target for immune-based interventions in gastric cancer therapy.
文章引用：赵立军, 渠海. KDM5亚家族在胃癌中的作用及免疫浸润的初步分析[J]. 临床医学进展, 2023, 13(10): 16002-16015. https://doi.org/10.12677/ACM.2023.13102236

参考文献

[1] Chiarella, A.M. and Lu, D. (2020) Epigenetic Control of a Local Chromatin Landscape. International Journal of Molec-ular Sciences, 21, Article No. 943. [Google Scholar] [CrossRef] [PubMed]
[2] Sarkar, R., Banerjee, S., Amin, S.A., et al. (2020) Histone Deacetylase 3 (HDAC3) Inhibitors as Anticancer Agents: A Review. European Journal of Medici-nal Chemistry, 192, Article ID: 112171. [Google Scholar] [CrossRef] [PubMed]
[3] Lu, C., Paschall, A.V., Shi, H., et al. (2017) The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. Journal of the National Cancer Institute, 109, djw283. [Google Scholar] [CrossRef] [PubMed]
[4] Johansson, C., Velupillai, S., Tumber, A., et al. (2016) Structural Analysis of Human KDM5B Guides Histone Demethylase Inhibitor Development. Nature Chemical Biology, 12, 539-545. [Google Scholar] [CrossRef] [PubMed]
[5] Dorosz, J., Kristensen, L.H., Aduri, N.G., Mirza, O., Lousen, R., Bucciarelli, S., Mehta, V., et al. (2019) Molecular Architecture of the Jumonji C Family Histone Demethylase KDM5B. Scientific Reports, 9, Article No. 4019. [Google Scholar] [CrossRef] [PubMed]
[6] Hao, F. (2021) Systemic Profiling of KDM5 Subfamily Signa-ture in Non-Small-Cell Lung Cancer. International Journal of General Medicine, 14, 7259-7275. [Google Scholar] [CrossRef] 
[7] Jim, M.A., Pinheiro, P.S., Carreira, H., Espey, D.K., Wiggins, C.L. and Weir, H.K. (2017) Stomach Cancer Survival in the United States by Race and Stage (2001-2009): Findings from the CONCORD-2 Study. Cancer, 123, 4994-5013. [Google Scholar] [CrossRef] [PubMed]
[8] Taniyama, Y., Katanoda, K., Charvat, H., Hori, M., Ohno, Y., Sasazuki, S., et al. (2017) Estimation of Lifetime Cumulative Incidence and Mortality Risk of Gastric Cancer. Japanese Journal of Clinical Oncology, 47, 1097-1102. [Google Scholar] [CrossRef] [PubMed]
[9] Janjigian, Y.Y., Sanchez-Vega, F., Jonsson, P., Chatila, W.K., Hechtman, J.F., Ku, G.Y., et al. (2018) Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 8, 49-58. [Google Scholar] [CrossRef] 
[10] Pectasides, E., Stachler, M.D., Derks, S., Liu, Y., Maron, S., Islam, M., et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery, 8, 37-48. [Google Scholar] [CrossRef] 
[11] Li, G., Kanagasabai, T., Lu, W., Zou, M.R., Zhang, S.M., Celada, S.I., Izban, M.G., Liu, Q., et al. (2020) KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Cancer Research, 80, 4633-4643. [Google Scholar] [CrossRef] 
[12] Li, L., Zhu, G., Tan, K., Jiang, L., Li, Y., Zhu, X., Lin, Z., Zhang, X., Chen, J. and Ma, C. (2022) CUX2/KDM5B/ SOX17 Axis Affects the Occurrence and Development of Breast Cancer. Endocrinology, 163, bqac110. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, J. and Nie, C. (2022) KDM5B Regulates the PTEN/PI3K/Akt Pathway to Increase Sorafenib-Resistance in Hepatocellular Carcinoma. Anticancer Drugs, 33, 840-849. [Google Scholar] [CrossRef] 
[14] Guo, J.C., Liu, Z., Yang, Y.J., Guo, M., Zhang, J.Q. and Zheng, J.F. (2021) KDM5B Promotes Self-Renewal of Hepatocellular Carcinoma Cells through the mi-croRNA-448-Mediated YTHDF3/ITGA6 Axis. Journal of Cellular and Molecular Medicine, 25, 5949-5962. [Google Scholar] [CrossRef] [PubMed]
[15] Zhao, X., Zhang, X., Zhang, X., Jiang, T., Zhai, J., Wang, H., et al. (2021) MiR-374b-5p Inhibits KDM5B-Induced Epithelial-Mesenchymal Transition in Pancreatic Cancer. American Journal of Cancer Research, 11, 3907-3920.
[16] Zhang, Z.G., Zhang, H.S., Sun, H.L., Liu, H.Y., Liu, M.Y. and Zhou, Z. (2019) KDM5B Promotes Breast Cancer Cell Proliferation and Migration via AMPK-Mediated Lipid Metabolism Reprogram-ming. Experimental Cell Research, 379, 182-190. [Google Scholar] [CrossRef] [PubMed]
[17] Pu, Y., Xiang, J. and Zhang, J. (2020) KDM5B-Mediated microRNA-448 Up-Regulation Restrains Papillary Thyroid Cancer Cell Pro-gression and Slows down Tumor Growth via TGIF1 Repression. Life Sciences, 250, Article ID: 117519. [Google Scholar] [CrossRef] [PubMed]
[18] Kuo, K.T., Huang, W.C., Bamodu, O.A., Lee, W.H., Wang, C.H., et al. (2018) Histone Demethylase JARID1B/ KDM5B Promotes Aggressiveness of Non-Small Cell Lung Cancer and Serves as a Good Prognostic Predictor. Clinical Epigenetics, 10, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
[19] Zhang, H., Liu, X., Chen, Y., Xu, R. and He, S. (2022) KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma. BioMed Research International, 2022, Article ID: 1556485. [Google Scholar] [CrossRef] [PubMed]
[20] Mocavini, I., Pippa, S., Licursi, V., Paci, P., Trisciuoglio, D., Manni-roni, C., Presutti, C. and Negri, R. (2019) JARID1B Expression and Its Function in DNA Damage Repair Are Tightly Regulated by miRNAs in Breast Cancer. Cancer Science, 110, 1232-1243. [Google Scholar] [CrossRef] [PubMed]
[21] Zhou, J., Yi, Q. and Tang, L. (2019) The Roles of Nuclear Focal Adhesion Kinase (FAK) on Cancer: A Focused Review. Journal of Experimental & Clinical Cancer Research, 38, Article No. 250. [Google Scholar] [CrossRef] [PubMed]
[22] Fattahi, S., Amjadi-Moheb, F., Tabaripour, R., Ashrafi, G.H. and Akhavan-Niaki, H. (2020) PI3K/AKT/mTOR Signaling in Gastric Cancer: Epigenetics and Beyond. Life Sciences, 262, Article ID: 118513. [Google Scholar] [CrossRef] [PubMed]
[23] He, H., Huang, J., Wu, S., Jiang, S., Liang, L., Liu, Y., et al. (2021) The Roles of GTPase-Activating Proteins in Regulated Cell Death and Tumor Immunity. Journal of Hematology & On-cology, 14, Article No. 171. [Google Scholar] [CrossRef] [PubMed]
[24] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. (2012) Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell, 149, 1060-1072. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, Y., Zheng, L., Shang, W., Yang, Z., Li, T., Liu, F., et al. (2022) Wnt/beta-Catenin Signaling Confers Ferroptosis Resistance by Targeting GPX4 in Gastric Cancer. Cell Death & Differentiation, 29, 2190-2202. [Google Scholar] [CrossRef] [PubMed]
[26] Gu, R., Xia, Y., Li, P., Zou, D., Lu, K., Ren, L., Zhang, H. and Sun, Z. (2022) Ferroptosis and Its Role in Gastric Cancer. Frontiers in Cell and Developmental Biology, 10, Article ID: 860344. [Google Scholar] [CrossRef] [PubMed]
[27] Nagamori, I., Kobayashi, H., Nishimura, T., Yamagishi, R., Katahira, J., Kuramochi-Miyagawa, S., Kono, T. and Nakano, T. (2018) Relationship between PIWIL4-Mediated H3K4me2 Demethylation and piRNA-Dependent DNA Methylation. Cell Reports, 25, 350-356. [Google Scholar] [CrossRef] [PubMed]
[28] Wong, P.P., Miranda, F., Chan, K.V., Berlato, C., Hurst, H.C. and Scibetta, A.G. (2012) Histone Demethylase KDM5B Collaborates with TFAP2C and Myc to Repress the Cell Cycle Inhibitor p21(cip) (CDKN1A). Molecular and Cellular Biology, 32, 1633-1644. [Google Scholar] [CrossRef] 
[29] Li, Y., Chen, L., Feng, L., Zhu, M., Shen, Q., Fang, Y., Liu, X. and Zhang, X. (2019) NEK2 Promotes Proliferation, Migration and Tumor Growth of Gastric Cancer Cells via Regulating KDM5B/H3K4me3. American Journal of Cancer Research, 9, 2364-2378.
[30] Maruhashi, T., Sugiura, D., Okazaki, I.M. and Okazaki, T. (2020) LAG-3: From Molecular Functions to Clinical Applications. The Journal for ImmunoTher-apy of Cancer, 8, e001014. [Google Scholar] [CrossRef] [PubMed]

为你推荐